^
Association details:
| Biomarker: | KIF5B-EGFR fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report
Published date:
06/14/2021
Excerpt:
Because of the detection of a KIF5B-EGFR fusion from a biopsy sample of metastatic supraclavicular LNs after disease progression, treatment with afatinib (40 mg qd) was initiated...After 2 months of afatinib treatment, CT examinations showed that partial response was achieved...In conclusion, we detected a novel KIF5B-EGFR fusion in advanced NSCLC as an indicator of a good response to afatinib therapy.
DOI:
https://doi.org/10.2147/OTT.S313896
